281 related articles for article (PubMed ID: 17108021)
1. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
Stanford MM; Barrett JW; Nazarian SH; Werden S; McFadden G
J Virol; 2007 Feb; 81(3):1251-60. PubMed ID: 17108021
[TBL] [Abstract][Full Text] [Related]
2. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.
Wang G; Barrett JW; Stanford M; Werden SJ; Johnston JB; Gao X; Sun M; Cheng JQ; McFadden G
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4640-5. PubMed ID: 16537421
[TBL] [Abstract][Full Text] [Related]
3. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus.
Werden SJ; McFadden G
Biochim Biophys Acta; 2008 Jan; 1784(1):228-37. PubMed ID: 17905673
[TBL] [Abstract][Full Text] [Related]
4. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
Lun XQ; Zhou H; Alain T; Sun B; Wang L; Barrett JW; Stanford MM; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2007 Sep; 67(18):8818-27. PubMed ID: 17875723
[TBL] [Abstract][Full Text] [Related]
5. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
6. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A.
Werden SJ; Barrett JW; Wang G; Stanford MM; McFadden G
J Virol; 2007 Mar; 81(5):2340-8. PubMed ID: 17151107
[TBL] [Abstract][Full Text] [Related]
7. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells.
Woo Y; Kelly KJ; Stanford MM; Galanis C; Chun YS; Fong Y; McFadden G
Ann Surg Oncol; 2008 Aug; 15(8):2329-35. PubMed ID: 18454298
[TBL] [Abstract][Full Text] [Related]
8. RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells.
Rahman MM; Gutierrez-Jensen AD; Glenn HL; Abrantes M; Moussatche N; McFadden G
J Virol; 2021 Jun; 95(14):e0015121. PubMed ID: 33952639
[TBL] [Abstract][Full Text] [Related]
9. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.
Stanford MM; McFadden G
Expert Opin Biol Ther; 2007 Sep; 7(9):1415-25. PubMed ID: 17727330
[TBL] [Abstract][Full Text] [Related]
10. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Urbasic AS; Hynes S; Somrak A; Contakos S; Rahman MM; Liu J; MacNeill AL
Am J Vet Res; 2012 Aug; 73(8):1252-61. PubMed ID: 22849686
[TBL] [Abstract][Full Text] [Related]
11. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA
Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.
Werden SJ; McFadden G
J Virol; 2010 Apr; 84(7):3287-302. PubMed ID: 20106927
[TBL] [Abstract][Full Text] [Related]
13. Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.
Rahman MM; Bagdassarian E; Ali MAM; McFadden G
Sci Rep; 2017 Nov; 7(1):15710. PubMed ID: 29146961
[TBL] [Abstract][Full Text] [Related]
14. Poxvirus host range genes.
Werden SJ; Rahman MM; McFadden G
Adv Virus Res; 2008; 71():135-71. PubMed ID: 18585528
[TBL] [Abstract][Full Text] [Related]
15. Replicating poxviruses for human cancer therapy.
Kim M
J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
[TBL] [Abstract][Full Text] [Related]
16. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
17. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
18. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
19. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
20. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
